REG - Anpario PLC - Full year trading statement

AnparioAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260119:nRSS3327Pa&default-theme=true

RNS Number : 3327P  Anpario PLC  19 January 2026

THIS ANNOUNCEMENT RELATES TO THE DISCLOSURE OF INFORMATION THAT QUALIFIED OR
MAY HAVE QUALIFIED AS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE
MARKET ABUSE REGULATION (EU) 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW BY
VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018.

 

Anpario plc
("Anpario", the "Group" or the "Company")

 

Full year trading statement

 

Anpario plc (AIM:ANP), the independent manufacturer of natural sustainable
animal feed additives for health, nutrition and biosecurity, provides the
following trading update for the year ended 31 December 2025 ("FY 2025"). The
figures set out in this announcement remain subject to audit.

 

Highlights (unaudited)

·      Revenue of approximately £47.1m (up 23% YoY; 2024: £38.2m)

·      Adjusted EBITDA expected to be not less than £9.4m (2024:
£7.0m)

·      Net cash as at 31 December 2025 of £12.4m (31 December 2024:
£10.5m)

 

Trading update

The Group delivered a stronger than expected operating performance in the
second half of 2025. Year-end sales were higher than anticipated, and the
Group now expects revenue for the 12 months ended 31 December 2025 to be
approximately £47.1m* (2024: £38.2m). This strong performance in revenue
combined with the Group's high operational gearing, will result in adjusted
EBITDA being ahead of current market expectations* and not less than £9.4m
(2024: £7.0m).

 

The results include a full-year contribution from Bio-Vet, which was acquired
on 30 September 2024, with integration activities progressing well and
according to plan. Bio-Vet saw one of its highest ever half-year sales
performances through H2 2025 with strong growth over the revenue achieved in
the first six months.

 

Excluding the contribution from Bio-Vet in both periods, the Group delivered a
broad-based increase in performance across territories and operating segments.
The Asia segment showed the most significant growth year on year, followed by
a strong performance in the Americas and Europe. The IMEA region saw a
reduction and consolidation in performance following high growth in the prior
year, albeit within which sales in India continued to grow significantly.

 

Financial position

Our financial position remains strong, with year-end cash balances of £12.4m*
(31 December 2024: £10.5m), after accounting for the final payment related to
the Bio-Vet acquisition, being £0.8m (USD 1.0m) of contingent consideration
which was earned in full and paid in Q4.

 

Our strong balance sheet enables the Group to invest in innovative natural
product solutions, expand our global reach and explore earnings enhancing and
complementary acquisitions to continue the profitable development of the
Group.

 

FY 2025 Results

The Group expects to publish its FY 2025 final results on or around 31 March
2026.

 

 

*Analyst consensus for FY 2025 immediately prior to this announcement was
Revenue of £45.5m, Adjusted EBITDA of £8.2m and net cash of £12.0m.

 

Enquiries

 

 Anpario plc
 Richard Edwards, Chief Executive Officer  +44(0)7776 417 129
 Marc Wilson, Group Finance Director       +44(0)1909 537 380

 Shore Capital
 (Nominated Adviser and Broker)            +44 (0) 20 7408 4090
 Stephane Auton                            Corporate Advisory
 David Coaten
 Tom Knibbs
 Henry Willcocks                           Corporate Broking

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TSTGPURAGUPQPUR



            Copyright 2019 Regulatory News Service, all rights reserved